MMRGlobal lays IP groundwork in Asia
HONG KONG – Most of Favrille Inc.’s market value vanished in 2008 after the firm said it would cease development of its active immunotherapy Specifid, which missed its primary endpoint in a pivotal phase III study in non-Hodgkin’s lymphoma. Almost a year later, San Diego-based Favrille merged with MyMedical-Records.com. The company once best known for providing health care IT services is just now stepping up its push into the biotechnology space in Asia.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter